Details

Autor(en) / Beteiligte

• Schwaiger, Elisabeth
• Krenn, Simon
• Kurnikowski, Amelie
• Bergfeld, Leon
• Pérez-Sáez, María José
• Frey, Alexander
• Topitz, David
• Bergmann, Michael
• Hödlmoser, Sebastian
• Bachmann, Friederike
• Halleck, Fabian
• Kron, Susanne
• Hafner-Giessauf, Hildegard
• Eller, Kathrin
• Rosenkranz, Alexander R
• Crespo, Marta
• Faura, Anna
• Tura, Andrea
• Song, Peter X K
• Port, Friedrich K
• Pascual, Julio
• Budde, Klemens
• Ristl, Robin
• Werzowa, Johannes
• Hecking, Manfred

Titel

Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial

Ist Teil von

• Journal of the American Society of Nephrology, 2021-08, Vol.32 (8), p.2083-2098

Ort / Verlag

United States: American Society of Nephrology

Erscheinungsjahr

2021

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Post-transplantation diabetes mellitus (PTDM) might be preventable. This open-label, multicenter randomized trial compared 133 kidney transplant recipients given intermediate-acting insulin isophane for postoperative afternoon glucose ≥140 mg/dl with 130 patients given short-acting insulin for fasting glucose ≥200 mg/dl (control). The primary end point was PTDM (antidiabetic treatment or oral glucose tolerance test-derived 2 hour glucose ≥200 mg/dl) at month 12 post-transplant. In the intention-to-treat population, PTDM rates at 12 months were 12.2% and 14.7% in treatment versus control groups, respectively (odds ratio [OR], 0.82; 95% confidence interval [95% CI], 0.39 to 1.76) and 13.4% versus 17.4%, respectively, at 24 months (OR, 0.71; 95% CI, 0.34 to 1.49). In the per-protocol population, treatment resulted in reduced odds for PTDM at 12 months (OR, 0.40; 95% CI, 0.16 to 1.01) and 24 months (OR, 0.54; 95% CI, 0.24 to 1.20). After adjustment for polycystic kidney disease, per-protocol ORs for PTDM (treatment versus controls) were 0.21 (95% CI, 0.07 to 0.62) at 12 months and 0.35 (95% CI, 0.14 to 0.87) at 24 months. Significantly more hypoglycemic events (mostly asymptomatic or mildly symptomatic) occurred in the treatment group versus the control group. Within the treatment group, nonadherence to the insulin initiation protocol was associated with significantly higher odds for PTDM at months 12 and 24. At low overt PTDM incidence, the primary end point in the intention-to-treat population did not differ significantly between treatment and control groups. In the per-protocol analysis, early basal insulin therapy resulted in significantly higher hypoglycemia rates but reduced odds for overt PTDM-a significant reduction after adjustment for baseline differences-suggesting the intervention merits further study. NCT03507829.